Compare PAYC & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAYC | UTHR |
|---|---|---|
| Founded | 1998 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9B | 20.3B |
| IPO Year | 2014 | 1999 |
| Metric | PAYC | UTHR |
|---|---|---|
| Price | $165.63 | $488.92 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 12 |
| Target Price | $225.42 | ★ $495.08 |
| AVG Volume (30 Days) | ★ 765.0K | 424.3K |
| Earning Date | 11-05-2025 | 10-29-2025 |
| Dividend Yield | ★ 0.91% | N/A |
| EPS Growth | N/A | ★ 16.08 |
| EPS | 8.05 | ★ 26.38 |
| Revenue | $2,001,300,000.00 | ★ $3,128,400,000.00 |
| Revenue This Year | $11.03 | $13.64 |
| Revenue Next Year | $8.85 | $5.78 |
| P/E Ratio | $20.59 | ★ $18.55 |
| Revenue Growth | 9.72 | ★ 13.50 |
| 52 Week Low | $156.50 | $266.98 |
| 52 Week High | $267.76 | $492.62 |
| Indicator | PAYC | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 41.79 | 68.10 |
| Support Level | $159.49 | $470.13 |
| Resistance Level | $164.54 | $492.62 |
| Average True Range (ATR) | 3.89 | 10.72 |
| MACD | 1.93 | -0.53 |
| Stochastic Oscillator | 68.49 | 89.55 |
Founded in 1998, Paycom is a human capital management software-as-a-service provider addressing customer requirements surrounding payroll, talent acquisition, talent management, HR management, as well as time and labor. The company primarily services midsize businesses within the United States, targeting businesses with 50-10,000 employees. The company primarily generates revenue through the sale of subscriptions providing access to its HCM platform. To a lesser extent, the company also generates revenue from implementation services provided to customers as well as interest income generated from customer funds. As of fiscal 2024, the company serviced slightly over 37,500 customers and stored data on over 7 million employees.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.